Oncopeptides Ab
- Country
- 🇧🇪Belgium
- Ownership
- Public
- Established
- 2000-01-01
- Employees
- 57
- Market Cap
- -
- Website
- http://www.oncopeptides.se
A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2021-11-26
- Lead Sponsor
- Oncopeptides AB
- Registration Number
- NCT04918511
- Locations
- 🇨🇿
University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology, Brno, Czechia
🇨🇿University Hospital Ostrava, Clinic of Hematooncology, Ostrava, Czechia
🇨🇿Charles University and General Hospital in Prague, 1st Department of Medicine - Department of Hematology, First Faculty of Medicine, Praha, Czechia
Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Oncopeptides AB
- Target Recruit Count
- 54
- Registration Number
- NCT04649060
- Locations
- 🇵🇱
Independent Public Healthcare Facility University Hospital in Krakow, Teaching Unit of the Hematology Department, Kraków, Poland
🇧🇬Specialized Hospital for Active Treatment of Hematological Diseases, Clinical Hematology Clinic, Sofia, Bulgaria
🇨🇿University Hospital Hradec Kralove, 4th Internal Clinic of Hematology, Kralovice, Czechia
Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Oncopeptides AB
- Registration Number
- NCT04534322
- Locations
- 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸Texas Oncology, Dallas, Texas, United States
A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM Patients
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Oncopeptides AB
- Target Recruit Count
- 27
- Registration Number
- NCT04412707
- Locations
- 🇺🇦
Public Non-Profit Enterprise "Kyiv City Clinical Hospital #9" under the Executive Body of Kyiv City Council, Hematology Department #1, Kyiv, Ukraine
🇨🇿University Hospital Olomouc, Clinic of Hemato-Oncology, Olomouc, Czechia
🇧🇬Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Sofia, Bulgaria
A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
- Conditions
- Interventions
- First Posted Date
- 2019-10-04
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Oncopeptides AB
- Target Recruit Count
- 6
- Registration Number
- NCT04115956
- Locations
- 🇬🇷
Alexandra General Hospital of Athens, Athen, Greece
🇮🇱Hadassah University Hospital Ein Kerem, Jerusalem, Israel
🇨🇿Fakultní Nemocnice Ostrava, Ostrava - Poruba, Czechia
PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal Function
- Conditions
- Interventions
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Oncopeptides AB
- Target Recruit Count
- 35
- Registration Number
- NCT03639610
- Locations
- 🇨🇿
University Hospital Olomouc, Clinic of Hemato-Oncology, Olomouc, Czechia
🇬🇷University General Hospital of Patras, Patra, Greece
🇬🇷General Hospital of Athens Alexandra, Therapeutic Clinic, Athens, Greece
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
- Conditions
- Interventions
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2022-12-19
- Lead Sponsor
- Oncopeptides AB
- Target Recruit Count
- 56
- Registration Number
- NCT03481556
- Locations
- 🇨🇿
Fakultní nemocnice Hradec Králové, Hradec Králové, Czechia
🇨🇿Fakultní nemocnice Ostrava, Ostrava, Czechia
🇫🇷Hôpital Morvan, Brest, France
A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide
- Conditions
- Interventions
- First Posted Date
- 2017-05-12
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Oncopeptides AB
- Target Recruit Count
- 495
- Registration Number
- NCT03151811
- Locations
- 🇨🇿
CZ-01, Ostrava, Czechia
🇺🇸US-19, Plantation, Florida, United States
🇺🇸US01, Fresno, California, United States
A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2022-11-22
- Lead Sponsor
- Oncopeptides AB
- Target Recruit Count
- 157
- Registration Number
- NCT02963493
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸Baylor, Dallas, Texas, United States
Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2020-10-23
- Lead Sponsor
- Oncopeptides AB
- Target Recruit Count
- 75
- Registration Number
- NCT01897714
- Locations
- 🇮🇹
Turin Hospital Myeloma Unit, Turin, Italy
🇩🇰Vejle Hospital, Vejle, Denmark
🇸🇪Sahlgrenska Hospital, Gothenburg, Sweden